Can I Take Alpha-Lipoic Acid with Prometrium?

What Is Prometrium and Why Do Women Take It?

Prometrium is the brand name for oral micronized progesterone, a bioidentical form of the hormone your ovaries produce naturally throughout your reproductive years. Unlike synthetic progestins such as medroxyprogesterone acetate, micronized progesterone has a molecular structure identical to endogenous progesterone and a different side-effect profile.

Women take Prometrium for several distinct reasons depending on life stage.

Postmenopausal hormone therapy

The most common indication is endometrial protection during menopause hormone therapy (MHT). Estrogen alone thickens the uterine lining; adding progesterone prevents endometrial hyperplasia and cancer. The ACOG Practice Bulletin on Menopause supports the use of progesterone in any woman with an intact uterus who takes systemic estrogen.

The standard postmenopausal MHT dose is 100 mg orally at bedtime for continuous combined regimens or 200 mg for 12 days per cycle on sequential regimens. Bedtime dosing is intentional: progesterone's metabolite allopregnanolone has sedative properties.

Perimenopause and cycle irregularity

During perimenopause, progesterone levels fall before estrogen does. Some clinicians prescribe Prometrium at 100-200 mg on cycle days 14-25 to reduce heavy bleeding and support sleep. This is an off-label but widely used approach. The Menopause Society (NAMS) 2022 Hormone Therapy Position Statement acknowledges progesterone's role in perimenopausal symptom management.

Luteal phase support in fertility treatment

Reproductive endocrinologists prescribe Prometrium vaginally (100-200 mg two to three times daily) or orally for luteal phase support in IVF cycles. ASRM guidelines on luteal phase support recognize progesterone supplementation as standard care after embryo transfer.

PCOS and progesterone deficiency

Women with PCOS frequently have anovulatory cycles and consequently low progesterone. Prometrium is sometimes prescribed cyclically to induce withdrawal bleeds and protect the endometrium. This use sits at the intersection of reproductive-age women and metabolic health, which is exactly where ALA tends to appear in supplement stacks.

What Is Alpha-Lipoic Acid and Why Do Women Take It?

Alpha-lipoic acid is a naturally occurring dithiol compound that functions as a cofactor in mitochondrial energy metabolism. It is both water- and fat-soluble, which makes it unusual among antioxidants. Your body makes small amounts; supplemental doses range from 300 mg to 1,200 mg daily.

Women specifically reach for ALA for several reasons.

Insulin sensitivity and PCOS

ALA improves insulin receptor signaling by activating GLUT4 translocation independently of insulin. A 2021 randomized controlled trial published in Nutrients found that 600 mg/day of ALA over 16 weeks significantly reduced HOMA-IR in women with PCOS compared to placebo. PCOS is the most common endocrine disorder in reproductive-age women, affecting roughly 8-13% of this population according to WHO. The overlap between PCOS management, metformin-like supplement use, and Prometrium prescribing is real and clinically important.

Neuropathy and metabolic health in midlife

Postmenopausal women with type 2 diabetes or prediabetes sometimes use ALA for peripheral neuropathy. The SYDNEY 2 trial showed that 600 mg intravenous ALA reduced neuropathy symptom scores by 52% compared to placebo. Oral data are weaker, but 600 mg/day oral ALA improved neuropathy scores over 4 weeks in that same program.

General antioxidant support during HRT

Some women add ALA to their supplement routine after starting HRT, drawn by its antioxidant reputation and potential metabolic benefits. This is where the Prometrium-plus-ALA combination most commonly arises in clinical practice.

The Two Real Interactions You Need to Know

Most drug-supplement interaction checkers flag Prometrium and ALA as a "moderate" or "monitor" pair. The concern is not a single dramatic interaction but two overlapping pharmacodynamic effects. Neither is purely pharmacokinetic (meaning ALA does not appear to significantly alter progesterone's absorption, protein binding, or CYP metabolism at typical doses), but both can shift your metabolic baseline in ways that matter.

Interaction 1: Hypoglycemic effects

Progesterone is not insulin-sensitizing; it can actually produce mild insulin resistance, particularly at luteal-phase levels. Synthetic progestins (especially medroxyprogesterone acetate) worsen glucose tolerance more than micronized progesterone does. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that micronized progesterone has a more favorable glycemic profile than synthetic progestins, but it is not metabolically neutral.

ALA moves in the opposite direction. At doses of 600-1,200 mg/day, it can lower fasting plasma glucose by approximately 10-15 mg/dL in insulin-resistant individuals, per a 2018 meta-analysis in Obesity Reviews. For most postmenopausal women on HRT without diabetes, this does not produce symptomatic hypoglycemia. The risk rises if you are also taking metformin, a GLP-1 receptor agonist (semaglutide, tirzepatide), or an SGLT2 inhibitor, because ALA's glucose-lowering adds to the drug's effect.

Who needs to watch this: Women with PCOS taking Prometrium cyclically who also use ALA to manage insulin resistance. Especially if you have added a GLP-1 medication, the three-way glucose-lowering stack requires monitoring.

Interaction 2: Thyroid hormone conversion

ALA inhibits the enzyme iodothyronine deiodinase, which converts T4 (thyroxine) to the more active T3 (triiodothyronine). A 2010 study in the Journal of Nutritional Biochemistry found that high-dose ALA reduced circulating T3 in rodent models. Human data remain thin, and this must be acknowledged plainly: we do not have a large randomized trial in women specifically examining ALA's effect on thyroid conversion at standard supplement doses.

Where does Prometrium fit in? Progesterone itself can modestly raise thyroxine-binding globulin (TBG) in some women, meaning total T4 looks higher on labs even when free T4 is unchanged. If you already have subclinical hypothyroidism or are on levothyroxine, adding ALA could theoretically reduce T3 generation at the same time that progesterone is shifting TBG. The net effect is hard to predict without your individual labs.

Who needs to watch this: Postmenopausal women who have Hashimoto's thyroiditis, who are on levothyroxine, or who have TSH trending above 2.5 mIU/L. Check TSH and free T4 within 6-8 weeks of starting ALA.

Is There a Pharmacokinetic Interaction?

Prometrium is metabolized primarily by CYP3A4 and CYP2C19. ALA does not appear to be a meaningful inhibitor or inducer of either enzyme at doses used in supplements (300-1,200 mg/day). So ALA is unlikely to raise or lower Prometrium blood levels by altering its metabolism.

ALA is absorbed quickly, peaks in plasma within 30-60 minutes, and has a short half-life of roughly 30 minutes for the parent compound. Prometrium taken orally at bedtime peaks at about 2-3 hours and produces sedating metabolites that persist overnight. The pharmacokinetic windows do not create a compounding absorption problem.

Dose separation is therefore not based on avoiding a metabolic drug-drug interaction; it is a practical choice to minimize overlapping pharmacodynamic glucose effects if that is your concern.

Dosing, Timing, and Practical Guidance

For most women using Prometrium at standard HRT doses (100-200 mg at bedtime) and ALA at 300-600 mg once daily, the simplest approach is:

• Take Prometrium at bedtime as prescribed.
• Take ALA with breakfast or lunch, away from the evening dose.
• Avoid taking ALA on an empty stomach if you are prone to GI upset; food slows absorption slightly but does not eliminate the glucose effect.
• Do not exceed 600 mg ALA daily without discussing it with your clinician if you are also managing blood sugar with medication.

The Natural Medicines Comprehensive Database interaction entry for alpha-lipoic acid rates its interaction with hypoglycemic agents as "moderate," meaning the combination requires awareness but is not contraindicated.

Pregnancy, Lactation, and Contraception

Prometrium in pregnancy

Prometrium is an FDA Pregnancy Category B drug based on older classifications (now replaced by the PRIS labeling system). Human data show no increased teratogenicity from micronized progesterone when used in the first trimester for luteal phase support. The FDA label for Prometrium explicitly states that it is used for luteal phase support in assisted reproductive technology (ART) programs.

Prometrium is NOT indicated for use beyond early pregnancy luteal support outside of specific clinical protocols. Women undergoing IVF or frozen embryo transfer typically take vaginal progesterone (or oral Prometrium off-label) through week 10-12 of pregnancy, when the placenta takes over progesterone production.

Prometrium does NOT require a specific contraception warning in the way that teratogenic drugs do (it is not a teratogen), but it should only be continued in pregnancy under direct clinical supervision.

Alpha-lipoic acid in pregnancy

ALA's safety data in human pregnancy is very limited. Animal studies have not shown teratogenicity at moderate doses, but no adequately powered human RCT has evaluated ALA specifically in pregnant women. Women who are pregnant or actively trying to conceive should not add or continue high-dose ALA (above approximately 200-300 mg/day) without explicit guidance from their OB or reproductive endocrinologist. This is an evidence gap, not a confirmed harm, but the precautionary position is warranted.

If you are taking Prometrium for luteal phase support after IVF and also using ALA for PCOS-related insulin resistance, discuss stopping or significantly reducing ALA once a confirmed pregnancy is established until better human data exist.

Lactation

Progesterone passes into breast milk in small amounts and is not considered harmful to a nursing infant. Prometrium is occasionally used postpartum to address progesterone deficiency, though this is uncommon because breastfeeding itself suppresses ovulation and progesterone fluctuates.

ALA transfer into breast milk has not been adequately studied. Because ALA affects glucose metabolism and the nursing infant's metabolic regulation is immature, a conservative approach is to avoid high-dose ALA while breastfeeding.

Who This Combination Is Right For (and Not Right For)

Most likely to benefit from using both

• Postmenopausal women on MHT for vasomotor symptoms who want antioxidant or neuropathy support, with no thyroid disease and no diabetes medications beyond lifestyle management.
• Perimenopausal women with PCOS who are taking cyclical Prometrium and ALA for insulin resistance, provided their glucose and thyroid are monitored.
• Women on MHT who have been using ALA for years and are newly starting Prometrium. The addition of Prometrium at standard HRT doses is unlikely to destabilize a well-established ALA regimen.

Requires extra caution or specialist input

• Women taking metformin, a GLP-1 agonist, or an SGLT2 inhibitor alongside Prometrium and ALA. Triple glucose-lowering mechanisms need monitoring.
• Women with Hashimoto's thyroiditis or on levothyroxine. The thyroid conversion concern is modest but real.
• Women with BMI <20 or a history of hypoglycemic episodes, where ALA's glucose-lowering could be more noticeable.
• Postmenopausal women using higher ALA doses (900-1,200 mg/day) for neuropathy. At these doses, the pharmacodynamic glucose and thyroid effects are more pronounced.

Not appropriate without specialist guidance

• Women actively pregnant beyond the luteal phase, given ALA's limited safety data.
• Women with known adrenal insufficiency, where glucose dysregulation from combined agents could be clinically significant.

What the Evidence Gap Looks Like, Honestly

There is no published randomized controlled trial that specifically examined micronized progesterone and alpha-lipoic acid co-administration in women. The interaction framework here is built from three separate bodies of evidence: ALA's pharmacology in insulin resistance, progesterone's metabolic effects in MHT trials, and thyroid deiodinase inhibition data from ALA studies, most of which used animal models or male-predominant populations.

Women have been historically underrepresented in metabolic supplement trials. The 2021 PCOS-specific ALA trial in Nutrients is one of the few to enroll exclusively female participants. Most earlier ALA trials enrolled mixed or predominantly male cohorts, meaning the glucose-lowering magnitude observed may differ in women, whose baseline insulin sensitivity shifts with cycle phase, hormonal status, and life stage.

The thyroid data is especially weak in women. The deiodinase inhibition study cited above used a rodent model. A careful clinician should treat the thyroid interaction as a signal worth monitoring, not a confirmed effect, and repeat thyroid labs are the correct response to that uncertainty, not avoiding the combination altogether.

Dr. Rachel Goldberg, MD, WomanRx editorial board OB-GYN, notes: "I see the Prometrium-plus-ALA combination regularly in perimenopausal women with PCOS. My standard practice is to check a fasting glucose and TSH at baseline and again at 8 weeks. In the absence of thyroid disease or active diabetes medication, I do not ask women to stop either agent. I do ask them to take ALA in the morning rather than at bedtime, simply to separate the glucose-lowering timing from Prometrium's overnight window."

Monitoring Checklist for Women Using Both

| What to monitor | When | Why | |---|---|---| | Fasting plasma glucose | Baseline and 8 weeks | ALA glucose-lowering effect | | TSH and free T4 | Baseline and 8 weeks if any thyroid history | ALA deiodinase inhibition | | Symptoms of hypoglycemia | Ongoing | Especially with concurrent diabetes medications | | Progesterone levels (serum or saliva per protocol) | Per HRT or fertility protocol | Ensure Prometrium levels remain therapeutic | | Endometrial ultrasound | Per MHT guidelines (annually if indicated) | Routine HRT monitoring, not ALA-specific |

Key Takeaways

• The combination is not contraindicated. Most women on standard Prometrium doses tolerate ALA at 300-600 mg/day without significant problems.
• The two interactions to manage are glucose lowering and potential thyroid T3 reduction.
• Morning ALA, bedtime Prometrium is a practical timing strategy.
• Women with PCOS using both agents for metabolic reasons need glucose monitoring, particularly if a GLP-1 medication is also in the picture.
• Pregnant women should pause high-dose ALA beyond the luteal support window until stronger human safety data exist.
• If your TSH was previously borderline or you are on levothyroxine, check thyroid labs 8 weeks after starting ALA.